Evidence map›Paper›PMID 41651836›Full record

ArticleNature communications2026

Author Correction: DKN-01 and tislelizumab as second-line therapy in DKK1-high gastroesophageal adenocarcinoma: DisTinGuish trial part B.

Keun-Wook Lee, Devalingam Mahalingam, Byoung Yong Shim, In-Ho Kim, Do-Youn Oh, Hope Uronis, Sun Jin Sym, Mohamad Sonbol, Khaldoun Almhanna, Mohamedtaki A Tejani and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Keun-Wook LeeDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. imdoctor@snu.ac.kr.
Devalingam MahalingamRobert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-2979-9894
Byoung Yong ShimThe Catholic University of Korea St. Vincent's Hospital, Suwon, Korea.ORCID http://orcid.org/0000-0001-6473-786X
In-Ho KimSeoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Do-Youn OhSeoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Hope UronisDuke University Medical Center, Durham, NC, USA.
Sun Jin SymGachon University Gil Medical Center, Incheon, Korea.
Mohamad SonbolMayo Clinic Hospital, Phoenix, AZ, USA.
Khaldoun AlmhannaRhode Island Hospital, Brown University Medical Center, Providence, RI, USA.
Mohamedtaki A TejaniAdvent Health Cancer Institute, Orlando, FL, USA.
Beodeul KangCHA Bundang Medical Center, Seongnam, Korea.
Michael H KageyLeap Therapeutics, Cambridge, MA, USA.
Melissa StilianLeap Therapeutics, Cambridge, MA, USA.
Calvin JiaLeap Therapeutics, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8732-6035
Cynthia A SirardLeap Therapeutics, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4856-4457
Rachel AlturaLeap Therapeutics, Cambridge, MA, USA.
Jaffer A AjaniMD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-9946-0629
Samuel J KlempnerDepartment of Medicine, Division of Hematology-Oncology, Massachusetts General Hospital, Boston, MA, USA. sklempner@mgb.org.ORCID http://orcid.org/0000-0002-4062-0808

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41651836
PMCPMC12881590

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.